Boostrix Drug Interactions

Boostrix can be given concomitantly with any of the following monovalent or combination vaccines: unadjuvanted inactivated seasonal influenza vaccines, human papilloma virus vaccines, meningococcal serogroups A, C, W-135 and Y (MenACWY) conjugate vaccines and non-live herpes zoster vaccine. Data have shown no clinically relevant interference in the antibody response to each of the vaccine antigens.
Clinical data from co-administration of Boostrix with a trivalent inactivated influenza vaccine in subjects aged between 19 and 64 years demonstrated that the immune responses to the tetanus, diphtheria, pertussis toxoid (PT) and influenza antigens were unaffected. Lower geometric mean concentrations (GMCs) were observed for the pertussis filamentous haemagglutinin (FHA) and pertactin (PRN) antigens; however, these data do not suggest clinically relevant interference. No differences were observed in a predefined exploratory cohort when the vaccines were given concomitantly or separately to subjects aged 65 years and older.
Clinical data from co-administration of Boostrix with non-live herpes zoster vaccine in subjects aged 50 years and older demonstrated that the immune responses to the tetanus, diphtheria, PT, FHA and herpes zoster antigens were unaffected. Lower GMCs were observed for the PRN antigen; however, these data do not suggest clinically relevant interference.
Clinical data from co-administration of Boostrix with MenACWY conjugate vaccines in subjects aged 9 to 25 years demonstrated that the immune responses to the tetanus, diphtheria and meningococcal antigens were unaffected. Lower GMCs were observed for the pertussis antigens; however, these data do not suggest clinically relevant interference.
Concomitant use with other inactivated vaccines and with immunoglobulin is unlikely to result in clinically relevant interference with the immune responses.
If Boostrix is to be given at the same time as another injectable vaccine or immunoglobulin, the products should always be administered at different sites.
As with other vaccines, patients receiving immunosuppressive therapy or patients with immunodeficiency may not achieve an adequate response. In these patients, when tetanus vaccine is needed for tetanus prone wound, plain tetanus vaccine will be used.